trending Market Intelligence /marketintelligence/en/news-insights/trending/f6WOXLokPGS0qxC61FwlRQ2 content esgSubNav
In This List

Chinese drug developer Allist Pharmaceuticals gets 1.18B yuan in financing

Podcast

Street Talk | Episode 94: Recessionary fears in ’22 overblown, Fed could overtighten

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Chinese drug developer Allist Pharmaceuticals gets 1.18B yuan in financing

Healthcare-focused private equity firm Shiyu Capital, also known as Shenzhen Shiyu Investment Management, led a 1.18 billion yuan series A funding round for Chinese drug developer Allist Pharmaceuticals Inc., DealStreetAsia reported, citing a company announcement.

Loyal Valley Capital and Suzhou Industrial Park Bioventure Investment Management Ltd. also supported the company, which focuses on the fields of cardiovascular, acid-related diseases and cancers, according to the report.

Allist will use the proceeds for drug research and for advancing product commercialization and foreign cooperation, the report noted.

As of May 24, US$1 was equivalent to 6.90 Chinese yuan.